Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO John F. Crowley sold 47,213 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $13.61, for a total value of $642,568.93. Following the transaction, the chief executive officer now directly owns 375,214 shares in the company, valued at approximately $5,106,662.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Amicus Therapeutics, Inc. (NASDAQ FOLD) traded up $0.03 during trading on Wednesday, reaching $12.54. The company’s stock had a trading volume of 1,823,624 shares, compared to its average volume of 3,179,943. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22. Amicus Therapeutics, Inc. has a 52-week low of $4.41 and a 52-week high of $16.60.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). The business had revenue of $10.90 million for the quarter, compared to analyst estimates of $9.02 million. Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The business’s revenue was up 419.0% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.33) earnings per share. sell-side analysts forecast that Amicus Therapeutics, Inc. will post -1.56 earnings per share for the current year.

A number of brokerages have weighed in on FOLD. Leerink Swann reissued a “buy” rating and set a $20.00 price target (up previously from $17.00) on shares of Amicus Therapeutics in a research report on Wednesday, October 4th. Robert W. Baird reaffirmed an “outperform” rating and issued a $16.00 target price on shares of Amicus Therapeutics in a research report on Monday, September 25th. J P Morgan Chase & Co reaffirmed an “overweight” rating and issued a $15.00 target price (up previously from $13.00) on shares of Amicus Therapeutics in a research report on Wednesday, August 9th. Cowen reaffirmed a “buy” rating and issued a $16.00 target price on shares of Amicus Therapeutics in a research report on Monday, August 14th. Finally, Zacks Investment Research downgraded Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 12th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Amicus Therapeutics currently has a consensus rating of “Buy” and an average target price of $17.81.

Hedge funds have recently added to or reduced their stakes in the company. Strs Ohio bought a new position in shares of Amicus Therapeutics during the 3rd quarter worth about $102,000. Teacher Retirement System of Texas boosted its position in shares of Amicus Therapeutics by 1.7% during the 2nd quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock worth $103,000 after purchasing an additional 169 shares in the last quarter. Tudor Investment Corp ET AL bought a new position in shares of Amicus Therapeutics during the 2nd quarter worth about $124,000. Aperio Group LLC boosted its position in shares of Amicus Therapeutics by 13.5% during the 2nd quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 1,663 shares in the last quarter. Finally, Zacks Investment Management bought a new position in shares of Amicus Therapeutics during the 2nd quarter worth about $145,000.

COPYRIGHT VIOLATION NOTICE: “Amicus Therapeutics, Inc. (FOLD) CEO Sells $642,568.93 in Stock” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/12/06/amicus-therapeutics-inc-fold-ceo-sells-642568-93-in-stock.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.